BR112012023017A8 - Fitocanabinóides no tratamento de câncer. - Google Patents

Fitocanabinóides no tratamento de câncer.

Info

Publication number
BR112012023017A8
BR112012023017A8 BR112012023017A BR112012023017A BR112012023017A8 BR 112012023017 A8 BR112012023017 A8 BR 112012023017A8 BR 112012023017 A BR112012023017 A BR 112012023017A BR 112012023017 A BR112012023017 A BR 112012023017A BR 112012023017 A8 BR112012023017 A8 BR 112012023017A8
Authority
BR
Brazil
Prior art keywords
cancer
phytocanabinoids
treatment
combination
temozolamide
Prior art date
Application number
BR112012023017A
Other languages
English (en)
Other versions
BR112012023017A2 (pt
Inventor
Parolaro Daniela
Massi Paola
Antonio Izzo Angelo
Borelli Francesca
Aviello Gabriella
Di Marzo Vincenzo
De Petrocellis Luciano
Schiano Moriello Aniello
Ligresti Alessia
Alexandra Ross Ruth
Ann Ford Lesley
Anavi-Goffer Sharon
Guzman Manuel
Velasco Guillermo
Lorente Mar
Torres Sofia
Kikuchi Tetsuro
Guy Geoffrey
Stott Colin
Wright Stephen
Sutton Alan
Potter David
De Meijer Etienne
Original Assignee
Otsuka Pharma Co Ltd
Gw Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42261478&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012023017(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd, Gw Pharma Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BR112012023017A2 publication Critical patent/BR112012023017A2/pt
Publication of BR112012023017A8 publication Critical patent/BR112012023017A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMBINAÇÃO DOS FITOCANABINÓIDES TETRAHIDROCANABINOL E CANABIDIOL JUNTOS COM TEMOZOLAMIDA E USO DA DITA COMBINAÇÃO NA FABRICAÇÃO DE UM MEDICAMENTO PARA TRATAR UM GLIOMA , Esta invenção está relacionada ao uso de fitocanabinóides, em uma forma isolada ou na forma de uma substância farmacológica botânica (BDS), no tratamento de câncer. De preferência, o câncer a ser tratado é câncer da próstata, câncer da mama ou câncer do cólon.
BR112012023017A 2010-03-12 2011-03-11 Fitocanabinóides no tratamento de câncer. BR112012023017A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1004137.4A GB2478595B (en) 2010-03-12 2010-03-12 Phytocannabinoids in the treatment of glioma
PCT/GB2011/050487 WO2011110866A1 (en) 2010-03-12 2011-03-11 Phytocannabinoids in the treatment of cancer

Publications (2)

Publication Number Publication Date
BR112012023017A2 BR112012023017A2 (pt) 2016-05-31
BR112012023017A8 true BR112012023017A8 (pt) 2018-04-03

Family

ID=42261478

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012023017A BR112012023017A8 (pt) 2010-03-12 2011-03-11 Fitocanabinóides no tratamento de câncer.

Country Status (27)

Country Link
US (3) US8790719B2 (pt)
EP (1) EP2544682B1 (pt)
JP (1) JP5785569B2 (pt)
KR (1) KR20130067248A (pt)
CN (1) CN102869356A (pt)
AR (1) AR080454A1 (pt)
AU (3) AU2011225837A1 (pt)
BR (1) BR112012023017A8 (pt)
CA (1) CA2792722A1 (pt)
CO (1) CO6630103A2 (pt)
CY (1) CY1117451T1 (pt)
DK (1) DK2544682T3 (pt)
EA (1) EA201290901A1 (pt)
ES (1) ES2569669T3 (pt)
GB (1) GB2478595B (pt)
HR (1) HRP20160427T1 (pt)
HU (1) HUE029817T2 (pt)
IL (1) IL221871A (pt)
MX (1) MX2012010512A (pt)
NZ (2) NZ629136A (pt)
PL (1) PL2544682T3 (pt)
SG (1) SG184016A1 (pt)
SI (1) SI2544682T1 (pt)
TW (1) TWI461205B (pt)
UA (1) UA109271C2 (pt)
WO (1) WO2011110866A1 (pt)
ZA (1) ZA201207574B (pt)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2377218A (en) * 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products
EP1811983B1 (en) 2004-11-16 2020-10-07 GW Pharma Limited New use for cannabinoid
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
GB2475183B (en) * 2008-06-04 2011-11-23 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2494461A (en) * 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
GB2514054A (en) * 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB201117956D0 (en) * 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
US9776014B2 (en) 2012-05-03 2017-10-03 Magdent Ltd. Bone enhancement device and method
EP2934512B1 (en) * 2012-12-18 2021-11-24 Kotzker Consulting LLC Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
WO2014134281A1 (en) 2013-02-28 2014-09-04 Full Spectrum Laboratories Limited Biosynthesis of cannabinoids
WO2017161387A1 (en) * 2016-03-18 2017-09-21 Reid Christopher Brian Compositions of natural extracts and use thereof in methods for preventing or treating diseases
EP2968259B1 (en) 2013-03-14 2022-09-14 SC Laboratories Inc. Bioactive concentrates and uses thereof
US10441617B2 (en) 2013-03-15 2019-10-15 Biotech Institute, Llc Breeding, production, processing and use of medical cannabis
MX2015013202A (es) 2013-03-15 2016-04-07 Biotech Inst Llc Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
GB2513167B (en) * 2013-04-18 2016-03-02 Otsuka Pharma Co Ltd Tetrahydrocannabivarin for use in the treatment of nausea and vomiting
GB2515312A (en) * 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
GB2516814B (en) * 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
US10774288B2 (en) * 2013-09-18 2020-09-15 The Werc Shop, LLC Terpene-based compositions, processes, methodologies for creation and products thereby
RU2016129536A (ru) * 2013-10-31 2018-01-31 Фулл Спектрум Лабораториз, Лтд. Препараты на основе терпенов и каннабиноидов
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
GB2527590A (en) * 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
AU2015292915B2 (en) 2014-07-21 2020-10-15 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal or sublingual administration of cannabinoids
CN106922153B (zh) 2014-08-25 2018-11-02 蒂威诺特科技有限公司 用于大麻素化合物的同时生产的设备和方法
CA2961410C (en) 2014-09-16 2023-07-11 India Globalization Capital, Inc. Cannabinoid composition and method for treating pain
US9844518B2 (en) 2014-09-30 2017-12-19 MJAR Holdings, LLC Methods of growing cannabaceae plants using artificial lighting
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
US9730911B2 (en) 2014-10-21 2017-08-15 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
CN104277917B (zh) * 2014-10-24 2018-02-09 汉康(云南)生物科技有限公司 一种富含大麻二酚的工业大麻精油提取方法及其提取设备
US10502750B2 (en) 2014-12-23 2019-12-10 Biotech Institute, Llc Reliable and robust method for the analysis of cannabinoids and terpenes in cannabis
WO2016118391A1 (en) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Composition and method for treating seizure disorders
WO2016123160A1 (en) 2015-01-26 2016-08-04 Biotech Institute, Llc Systems, apparatuses, and methods for classification
AU2016211314A1 (en) 2015-01-31 2017-08-17 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
WO2016138505A1 (en) 2015-02-27 2016-09-01 Ebbu, LLC Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
EP3261629A4 (en) * 2015-02-27 2018-12-05 Ebbu, LLC Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
EP3277260B1 (en) 2015-04-01 2021-05-12 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Erodium crassifolium l'her plant extracts and uses thereof
PT3291807T (pt) * 2015-05-07 2020-01-10 Res Grow Labs Hidrogenação de óleo de cannabis
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
CA2991530C (en) * 2015-07-06 2023-12-12 Cg-Bio Genomics, Inc. Supplement compositions comprising oils, cannabis and herbal extracts, and uses thereof
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
WO2017027651A1 (en) * 2015-08-12 2017-02-16 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
MX2018006381A (es) * 2015-11-24 2019-02-14 Constance Therapeutics Inc Composiciones de aceite de cannabis y metodos para preparacion de las mismas.
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
EP3471746A4 (en) 2016-06-15 2020-02-26 India Globalization Capital, Inc. METHOD AND COMPOSITION FOR TREATING EPILEPTIC DISORDERS
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
JP2019526541A (ja) * 2016-08-03 2019-09-19 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 大麻組成物
BR112019001852A2 (pt) * 2016-08-03 2019-05-07 Zelda Therapeutics Operations Pty Ltd composição de cannabis
SG11201900596XA (en) * 2016-08-03 2019-02-27 Zelda Therapeutics Operations Pty Ltd Cannabis composition
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
EP3503875A4 (en) 2016-08-29 2020-06-24 Canopy Growth Corporation WATER-SOLUBLE COMPOSITIONS WITH CLEANED CANNABINOIDS
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
EP3589129A4 (en) * 2017-03-01 2020-11-25 Canopy Growth Corporation USEFUL COMPOSITIONS SELECTED WITH PURIFIED CANNABINOIDS AND / OR PURIFIED TERPENS
CA3055060A1 (en) * 2017-03-05 2018-09-13 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Compositions and methods for treating cancer
WO2018205038A1 (en) * 2017-05-12 2018-11-15 Tetra Bio-Pharma Inc. Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling
EP3630063A2 (en) 2017-05-22 2020-04-08 GBS Global Biopharma, Inc. Myrcene-containing complex mixtures targeting trpv1
WO2018235079A1 (en) 2017-06-20 2018-12-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. CANNABIDIOLIC ACID ESTER COMPOSITIONS AND USES THEREOF
CN111629724A (zh) * 2017-09-02 2020-09-04 科学控股公司 四氢大麻酚调节剂
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
CN108204786A (zh) * 2018-01-15 2018-06-26 武汉盛硕电子有限公司 一种基于手机模块的北斗测量系统
US10688191B2 (en) 2018-01-19 2020-06-23 Hr Biomed, Llc Delivery of a chemotherapy agent across the blood-brain barrier
US20210038559A1 (en) * 2018-01-22 2021-02-11 Thomas Richard Gadek Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
WO2019157195A1 (en) * 2018-02-08 2019-08-15 Neonc Technologies, Inc Methods of permeabilizing the blood brain barrier
KR102041875B1 (ko) 2018-02-14 2019-11-08 (주)카이언바이오텍 대마로부터 추출된 칸나비디올 추출물 및 트레일을 함유하는 대장암 예방 또는 치료용 약학 조성물
KR20190098649A (ko) 2018-02-14 2019-08-22 (주)카이언바이오텍 칸나비디올 추출물을 함유하는 대장암 예방 또는 치료용 약학 조성물
CN113264914A (zh) * 2018-02-20 2021-08-17 麦姆德制药(佛罗里达)公司 用于治疗物质成瘾和其它障碍的遗传修饰的大麻植物和修饰的大麻素化合物
AU2019249887A1 (en) 2018-04-04 2020-10-22 Akos Biosciences, Inc. Combination of a cannabinoid and a chemotheraopeutic agent for the treatment of breast cancer
CN112969452A (zh) 2018-04-09 2021-06-15 艾乐文特科学公司 用于治疗动物疼痛的大麻提取物
WO2019227167A1 (en) * 2018-06-01 2019-12-05 The University Of Sydney Compositions and treatments
WO2020012315A1 (en) * 2018-07-08 2020-01-16 Buzzelet Development And Technologies Ltd. Terpene-enriched cannabinoid composition for treatment of male subjects
EP3666765A1 (en) * 2018-12-11 2020-06-17 Emerald Health Biotechnology España,S.L.U. Chromenic phytocannabinoids, their synthesis and use in treatment or prevention of disease
WO2020121312A1 (en) * 2018-12-12 2020-06-18 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Compositions and methods for the treatment of cutaneous t cell lymphoma (ctcl)
US20220105051A1 (en) * 2019-01-31 2022-04-07 Cava Healthcare Inc. Compounds for increasing mhc-i expression and modulating histone deacetylase activity
WO2020206132A1 (en) * 2019-04-02 2020-10-08 Ulagaraj Selvaraj Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening and immediate drug release following intravenous administration
CA3102473C (en) * 2019-05-03 2021-07-06 Zyus Life Sciences Inc. Formulation for pain management
CN114096241A (zh) * 2019-05-16 2022-02-25 技术研究及发展基金有限公司 大麻素及其用途
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
CN111184710A (zh) * 2020-03-02 2020-05-22 福建省中科生物股份有限公司 一种环酚的应用和制备方法
US20220226259A1 (en) 2020-04-29 2022-07-21 Vivacell Biotechnology España S.L. Cannabinoids for use in supressing cancer stem cells
EP3912485A1 (en) 2020-05-18 2021-11-24 Del-Vis Sp. z o.o. Cigarette product and a method for manufacturing the product
CN111773390B (zh) * 2020-07-01 2021-08-20 南京大学 一种药物在制备治疗脑转移瘤及其相关疾病的药品中的应用
WO2022043961A1 (en) * 2020-08-31 2022-03-03 Nelson Mandela University Cannabinoid combinations and their use in the treatment of cancer
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
WO2022123566A1 (en) * 2020-12-08 2022-06-16 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Institute) Compositions and methods for the treatment of urothelial cancer
EP4319741A1 (en) * 2021-04-05 2024-02-14 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Institute) Compositions and methods for the treatment of cancer
WO2023076928A1 (en) 2021-10-26 2023-05-04 Ecofibre Limited Methods of treating ovarian cancer with hemp extract
IL312245A (en) 2021-10-26 2024-06-01 Ecofibre Usa Inc Methods of treating endometriosis and other non-cancerous gynecological disorders with hemp extract
WO2023130161A1 (en) * 2022-01-10 2023-07-13 Dolce Cann Global Pty Ltd Compositions and methods for treating non-neurological disorders with combination products comprising a cannabinoid mixture rich in cannabidiolic acid (cbda) along with an additional active agent
WO2023130160A1 (en) * 2022-01-10 2023-07-13 Dolce Cann Global Pty Ltd Compositions and methods for treating non-neurological disorders with combination products comprising a cannabinoid mixture rich in cannabidiolic acid (cbda).
WO2023161921A2 (en) * 2022-02-23 2023-08-31 Cannabotech Ltd. Compositions for use as an adjunctive therapy in the treatment of breast cancer
WO2023238114A1 (en) * 2022-06-08 2023-12-14 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Institute) Combinations and methods for the treatment of cancer
WO2023239415A1 (en) * 2022-06-08 2023-12-14 Angrow Company Limited Compositions including cannabinoid and use thereof in the manufacture of a medicament for the treatment of inflammation in a subject
WO2024082014A1 (en) * 2022-10-21 2024-04-25 Dolce Cann Global Pty Ltd Compositions comprising cannabidiolic acid and fatty acids
WO2024091989A1 (en) 2022-10-26 2024-05-02 Ecofibre USA Inc. Stabilized compositions comprising cannabidiol
CN115583933B (zh) * 2022-10-31 2024-02-06 暨明医药科技（苏州）有限公司 一种高纯度四氢大麻素同系物的制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2238707A (en) 1989-12-08 1991-06-12 Peter Bullock Repairing footwear
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US20040039048A1 (en) 2000-02-11 2004-02-26 Manuel Guzman Pastor Therapy with cannabinoid compounds for the treatment of brain tumors
ES1045342Y (es) 2000-02-11 2001-02-16 Alvarez Manuel Couto Expositor giratorio para postales, fotos y similares.
ES2164584A1 (es) 2000-02-11 2002-02-16 Univ Madrid Complutense Terapia con cannabinoides para el tratamiento de tumores cerebrales.
US6448288B1 (en) 2000-05-17 2002-09-10 University Of Massachusetts Cannabinoid drugs
WO2002022858A1 (en) 2000-09-14 2002-03-21 The Regents Of The University Of California Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
US7025992B2 (en) 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
GB2380129B (en) 2001-02-14 2004-08-11 Gw Pharma Ltd Pharmaceutical formulations
CH695661A5 (de) 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
GB0202385D0 (en) * 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
US8034843B2 (en) 2002-02-01 2011-10-11 Gw Pharma Limited Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions
US20080057117A1 (en) 2002-02-15 2008-03-06 Forschungs Institut Miscia Verenfur Krebsforschung Pharmaceutical composition made up of cannibus extracts
IL148244A0 (en) 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
WO2003091189A1 (en) 2002-04-25 2003-11-06 Virginia Commonwealth University Cannabinoids
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
GB2391865B (en) 2002-08-14 2005-06-01 Gw Pharma Ltd Improvements in the extraction of pharmaceutically active components from plant materials
GB2394894B (en) 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
GB2414933B (en) 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
GB2418612A (en) 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
US7638558B2 (en) 2005-04-01 2009-12-29 Intezyne Technologies, Inc. Polymeric micelles for drug delivery
US7968594B2 (en) 2005-04-27 2011-06-28 Gw Pharma Limited Pharmaceutical compositions for the treatment of pain
CA2608399A1 (en) 2005-05-13 2006-11-23 Unimed Pharmaceuticals, Inc. Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting
GB2434312B (en) * 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
GB2438682A (en) 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
US20080103193A1 (en) * 2006-10-26 2008-05-01 Trevor Percival Castor Methods for making compositions and compositions for treating pain and cachexia
US20100152238A1 (en) * 2007-03-05 2010-06-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel quinonoid derivatives of cannabinoids and their use in the treatment of malignancies
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
WO2008144475A1 (en) 2007-05-17 2008-11-27 California Pacific Medical Center Methods and compositions for treating cancer
GB2449691A (en) * 2007-05-31 2008-12-03 Gw Pharma Ltd A reference plant lacking medicinal active compound expression
GB2450741A (en) * 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
ES2359168T3 (es) * 2007-10-02 2011-05-19 Vivacell Biotechnology España S.L. Composición que comprende cannabinoides no psicotrópicos para el tratamiento de enfermedades antiinflamatorias.
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
GB2475183B (en) * 2008-06-04 2011-11-23 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma

Also Published As

Publication number Publication date
JP5785569B2 (ja) 2015-09-30
ZA201207574B (en) 2014-09-25
MX2012010512A (es) 2012-10-15
AU2016266059A1 (en) 2016-12-22
NZ602953A (en) 2014-09-26
JP2013522184A (ja) 2013-06-13
BR112012023017A2 (pt) 2016-05-31
WO2011110866A1 (en) 2011-09-15
AU2018217273A1 (en) 2018-08-30
UA109271C2 (uk) 2015-08-10
KR20130067248A (ko) 2013-06-21
HRP20160427T1 (hr) 2016-07-01
GB201004137D0 (en) 2010-04-28
US9675654B2 (en) 2017-06-13
HUE029817T2 (en) 2017-04-28
EP2544682B1 (en) 2016-02-10
AU2018217273B2 (en) 2020-03-12
CN102869356A (zh) 2013-01-09
US8790719B2 (en) 2014-07-29
ES2569669T3 (es) 2016-05-12
EA201290901A1 (ru) 2013-04-30
CY1117451T1 (el) 2017-04-26
SG184016A1 (en) 2012-10-30
CA2792722A1 (en) 2011-09-15
CO6630103A2 (es) 2013-03-01
AR080454A1 (es) 2012-04-11
NZ629136A (en) 2016-03-31
IL221871A (en) 2017-03-30
TWI461205B (zh) 2014-11-21
DK2544682T3 (en) 2016-05-09
US20180042975A1 (en) 2018-02-15
GB2478595B (en) 2018-04-04
US20130059018A1 (en) 2013-03-07
SI2544682T1 (sl) 2016-06-30
TW201201828A (en) 2012-01-16
PL2544682T3 (pl) 2016-08-31
AU2011225837A1 (en) 2012-11-01
GB2478595A (en) 2011-09-14
EP2544682A1 (en) 2013-01-16
US20150086653A1 (en) 2015-03-26

Similar Documents

Publication Publication Date Title
BR112012023017A8 (pt) Fitocanabinóides no tratamento de câncer.
UA104426C2 (uk) Протипухлинні ефекти комбінацій канабіноїдних сполук
TN2013000508A1 (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
MX2013013809A (es) Dispositivos expandibles con revestimiento de una composicion de paclitaxel.
DOP2012000155A (es) Terapia combinada para el tratamiento del cancer y ensayos de diagnostico relacionados
BR112013007681A2 (pt) uso terapêutico de um agonista trl e terapia de combinação
CL2015002807A1 (es) Terapia de combinación
MX2010006991A (es) Tratamientos de cancer terapeuticos.
SV2011003901A (es) Compuestos de arilo con sustituyentes heterocíclicos como inhibidores de hif
BR112014031088A8 (pt) métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
IL192908A0 (en) Hydrogel
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
MX2014000777A (es) Cateter, en particular cateter permanente para el tratamiento de disfunciones y/o enfermedades de la vejiga y/o la prostata.
BRPI0810384B8 (pt) terapia enzimática anticâncer
MX2013008175A (es) Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
TN2013000333A1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
MX2013013808A (es) Dispositivos expandibles con revestimiento de una composicion de rapamicina.
MX2014012535A (es) Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.
CL2011003248A1 (es) Composicion farmaceutica que comprende crf y un inhibidor de angiogenesis; util para la prevencion y el tratamiento del cancer.
BR112014030406A8 (pt) combinação de canabidiol fitocanabinoide com hipotermia terapêutica, e, uso de uma combinação
BR112013000945A2 (pt) atadura para tratar doenças da pele e para aliviar os sintomas de doenças da pele envolvendo exsudação das proteínas do sangue
MX337705B (es) Uso terapeutico de conjugados proteina-polimero.
NZ713046A (en) Therapeutic compositions for the treatment and prevention of gastrointestinal cancer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: GW PHARMA LIMITED (GB) , OTSUKA PHARMACEUTICAL CO., LTD (JP)

Owner name: GW PHARMA LIMITED (GB) , OTSUKA PHARMACEUTICAL CO.

B25A Requested transfer of rights approved

Owner name: GW PHARMA LIMITED (GB)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: GW PHARMA LIMITED (GB)

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B11R Patent application dismissed according to article 229 of the patent law [chapter 11.18 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2621 DE 30/03/2021.